Don’t Go Bargain Hunting on Aprea Stock, Says Analyst

TipRanks2020-12-30

The stock market is often witness to extreme stock gyrations, though hardly any more so following the impact of clinical trial results – good or bad. Unfortunately for Aprea Therapeutics (APRE), the ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2095721905?lang=zh_CN&edition=full","thumbnail":"https://s.yimg.com/uu/api/res/1.2/QBGE2Wowdy6q2OTAjNDgMA--~B/aD00MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/h5yeOm7Va_oWkr_FKMkAxA--~B/aD00MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en-US/tipranks_452/d3beb91bad460d624febb1815b2fd0ff","is_english":true,"pubTime":"2020-12-30 08:24","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2095721905","market":"us","top_or_hot":-1,"title":"Don’t Go Bargain Hunting on Aprea Stock, Says Analyst","media":"TipRanks","content":"<div>\n<p>The stock market is often witness to extreme stock gyrations, though hardly any more so following the impact of clinical trial results – good or bad.\nUnfortunately for Aprea Therapeutics (APRE), the ...</p>\n\n<a href=\"https://finance.yahoo.com/news/don-t-bargain-hunting-aprea-002457187.html\">网页链接</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Don’t Go Bargain Hunting on Aprea Stock, Says Analyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDon’t Go Bargain Hunting on Aprea Stock, Says Analyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n2020-12-30 08:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/don-t-bargain-hunting-aprea-002457187.html><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The stock market is often witness to extreme stock gyrations, though hardly any more so following the impact of clinical trial results – good or bad.\nUnfortunately for Aprea Therapeutics (APRE), the ...</p>\n\n<a href=\"https://finance.yahoo.com/news/don-t-bargain-hunting-aprea-002457187.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"APRE","symbol_name":"Aprea Therapeutics, Inc.","start_time":0,"source_url":"https://finance.yahoo.com/news/don-t-bargain-hunting-aprea-002457187.html","article_id":"2095721905","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/QBGE2Wowdy6q2OTAjNDgMA--~B/aD00MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/h5yeOm7Va_oWkr_FKMkAxA--~B/aD00MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en-US/tipranks_452/d3beb91bad460d624febb1815b2fd0ff"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/don-t-bargain-hunting-aprea-002457187.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2095721905","pubTimestamp":1609287897,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"The stock market is often witness to extreme stock gyrations, though hardly any more so following th","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"APRE":"Aprea Therapeutics, Inc."},"translate_title":"分析师表示，不要逢低买入Aprea股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APRE":0.9},"content_text":"The stock market is often witness to extreme stock gyrations, though hardly any more so following the impact of clinical trial results – good or bad.\nUnfortunately for Aprea Therapeutics (APRE), the stock’s latest move was down to the latter.\nThis week, Aprea shares cratered by 80% (yes, 80), after the biopharma’s lead therapeutic candidate failed to impress in a late-stage trial.\nSpecifically, in the Phase 3 trial of MDS (myelodysplastic syndrome) treatment eprenetapopt, the drug failed to meet the primary endpoint of complete remission (CR).\nWhile the drug’s results improved on those of the control arm, they failed to do so in a statistically significant manner (33% vs 22.4%).\nAs the baseline characteristics were similar to those of the Phase 1 and 2 studies, the company is now further analyzing the data to understand the CR rate’s ~70% drop.\nMeanwhile, focus will turn to other programs in Aprea’s pipeline, including in AML (acute myeloid leukemia), CLL (chronic lymphocytic leukemia), and solid tumors. \nBut for RBC analyst Gregory Renza, the damage is done, and the results necessitate a rejig of his Aprea model.\n“While the company continues to proceed with other pipeline programs around eprenetapopt, we believe the news has an adverse read-through to the path forward and lowers our confidence in the potential of the molecule and the programs,” the 5-star analyst said. “We look to the data updates from the programs in 2021 for additional insights into the activity of epr and APR-548 in other indications, though we believe the MDS PE miss reads through to the earlier pipeline programs and lowers our expectation on the data readouts.”\nAccordingly, Renza downgraded Aprea’s rating from Outperform (i.e. Buy) to Sector Perform (i.e. Hold) and slashed the price target from $40 to $10. That said, following the sharp share decline, there is still potential upside of a hefty 98% from current levels. (To watch Renza’s track record, click here)\nWall Street believes Renza is smart to play it safe when it comes to the Aprea's prospects ahead, as TipRanks analytics reveal the stock as a Hold. Out of 5 analysts polled in the past week, four say Hold, while only one suggests Buy. With a potential upside of 46%, the consensus price target stands at $7.40. Yet, the analysts are not convinced the reward is worth all the risk. (See APRE stock analysis on TipRanks)\n\n\n\n\n\nTo find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.\nDisclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2095721905"}